Eli Lilly and Company announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase III...
The FDA has approved Verzenio (abemaciclib) from Eli Lilly, to treat adult patients who have hormone receptor (HR)-positive, human epidermal...
Eli Lilly and Company announced that the FDA has approved Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as...
Eli Lilly and Company announced that the FDA approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence.
Eli Lilly and Company announced Verzenio (abemaciclib; CDK4/6 inhibitor) and Jaypirca (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO Annual Meeting in Chicago, June 2 – 6, 2023.
Eli Lilly and Company announced new data for the investigational use of Verzenio (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO) .
Eli Lilly and Company announced Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.747; 95% CI: 0.598, 0.932; p = 0.0096).
Eli Lilly and Company announced that its Phase III JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6...
Overall survival (OS) data from Eli Lilly and Company's Verzenio (abemaciclib) Phase III monarchE study were published in a Letter to the Editor in the Annals of Oncology.
Eli Lilly announced updated results from the pivotal Phase III monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC)